Standard BioTools Inc (FRA:FLB)
€ 1.67 0 (0%) Market Cap: 589.28 Mil Enterprise Value: 320.41 Mil PE Ratio: 0 PB Ratio: 1.24 GF Score: 52/100
Back to the Transcripts List

Q3 2024 Standard BioTools Inc Earnings Call Transcript

Oct 30, 2024 / 08:30PM GMT
Release Date Price: €1.7 (+15.65%)

Key Points

Positve
  • Standard BioTools Inc (LAB) achieved a sequential revenue increase of 21% from the previous quarter, indicating operational improvements.
  • The company has successfully integrated SomaLogic, achieving $80 million in expected synergies a year ahead of schedule.
  • Consumables revenue grew by 13% year-over-year, highlighting a strong margin profile and strategic focus.
  • The company has improved its on-time delivery rate to 98%, significantly enhancing customer satisfaction and operational efficiency.
  • Standard BioTools Inc (LAB) has a robust cash position with $368 million in cash and short-term investments, supporting its strategic vision.
Negative
  • Year-over-year revenue declined by 5% for the quarter and 9% year-to-date, reflecting ongoing market challenges.
  • Instruments revenue fell by 42% year-over-year, impacted by capital spending constraints and weakness in China.
  • The company faces a $15 million to $20 million headwind from its top five SomaScan customers, affecting service revenue.
  • Operating in a challenging environment with conservative customer purchasing behaviors, impacting growth potential.
  • Despite improvements, the company is still navigating gross margin headwinds and onetime costs, affecting profitability.
Operator

Good day, and welcome to the Standard BioTools Inc. third-quarter 2024 financial results conference call. (Operator Instructions) Please note, this event is being recorded. I would now like to turn the conference over to David Holmes of Investor Relations. Please go ahead.

David Holmes
Gilmartin Group LLC - Investor Relations

Thank you, operator, and good afternoon, everyone. Welcome to Standard BioTools third-quarter 2024 earnings conference call. Leading the call today is Michael Egholm, President and Chief Executive Officer; and Alex Kim, Chief Operating Officer and Interim Chief Financial Officer.

At the close of market today, Standard BioTools released its financial results for the quarter ended September 30, 2024. During this call, we will review our results and provide an update of our financial and operational performance, 2024 outlook, market trends and strategic initiatives.

During the call, we will make forward-looking statements about events and circumstances that have not yet occurred, including plans and projections for our

Already have an account? Log in
Get the full story
Start 7-Day Free Trial
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot
Research Tools
All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board
Product
Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文
Education
Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation
Company
About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program
Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey
Follow Us
download GuruFocus on Apple store download GuruFocus on Google Play
Disclaimers
GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.
© 2004-2025 GuruFocus.com, LLC. All Rights Reserved.